TY - JOUR
T1 - The therapeutic potential of targeting the peripheral endocannabinoid/CB1 receptor system
AU - Tam, Joseph
AU - Hinden, Liad
AU - Drori, Adi
AU - Udi, Shiran
AU - Azar, Shahar
AU - Baraghithy, Saja
N1 - Publisher Copyright: © 2018 European Federation of Internal Medicine
PY - 2018/3
Y1 - 2018/3
N2 - Endocannabinoids (eCBs) are internal lipid mediators recognized by the cannabinoid-1 and -2 receptors (CB1R and CB2R, respectively), which also mediate the different physiological effects of marijuana. The endocannabinoid system, consisting of eCBs, their receptors, and the enzymes involved in their biosynthesis and degradation, is present in a vast number of peripheral organs. In this review we describe the role of the eCB/CB1R system in modulating the metabolism in several peripheral organs. We assess how eCBs, via activating the CB1R, contribute to obesity and regulate food intake. In addition, we describe their roles in modulating liver and kidney functions, as well as bone remodeling and mass. Special importance is given to emphasizing the efficacy of the recently developed peripherally restricted CB1R antagonists, which were pre-clinically tested in the management of energy homeostasis, and in ameliorating both obesity- and diabetes-induced metabolic complications.
AB - Endocannabinoids (eCBs) are internal lipid mediators recognized by the cannabinoid-1 and -2 receptors (CB1R and CB2R, respectively), which also mediate the different physiological effects of marijuana. The endocannabinoid system, consisting of eCBs, their receptors, and the enzymes involved in their biosynthesis and degradation, is present in a vast number of peripheral organs. In this review we describe the role of the eCB/CB1R system in modulating the metabolism in several peripheral organs. We assess how eCBs, via activating the CB1R, contribute to obesity and regulate food intake. In addition, we describe their roles in modulating liver and kidney functions, as well as bone remodeling and mass. Special importance is given to emphasizing the efficacy of the recently developed peripherally restricted CB1R antagonists, which were pre-clinically tested in the management of energy homeostasis, and in ameliorating both obesity- and diabetes-induced metabolic complications.
KW - Bone remodeling
KW - CB receptor
KW - Chronic kidney disease
KW - Endocannabinoids
KW - NAFLD
KW - Obesity
UR - http://www.scopus.com/inward/record.url?scp=85040321172&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ejim.2018.01.009
DO - https://doi.org/10.1016/j.ejim.2018.01.009
M3 - مقالة مرجعية
C2 - 29336868
SN - 0953-6205
VL - 49
SP - 23
EP - 29
JO - European Journal of Internal Medicine
JF - European Journal of Internal Medicine
ER -